

# Malarone - (100/250 mg; Tablet)

| Generic Name          | Atovaquone and Proguanil Hydrochloride  | Innovator            | GlaxoSmithkline     |
|-----------------------|---|----------------------|---------------------|
| Dosage                | 100/250 mg; Tablet  | Branded US Sales     | Less Than \$1000 mn |
| Probable FTF          | Less Than 5   | Known Para IV Filers | Less Than 5         |
| Other ANDA developers | Less Than 5   | Tentative Approvals  | None                |
| Final Approvals       | Less Than 5   | Generic Launches     | Less Than 5         |
| Indication            | Indicated for: prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. |                      |                     |
| Complexities          | Yes   |                      |                     |

# **Chronology Of Events**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

### **Executive Summary**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

## **Patent Status**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

### Launch Timelines and Competition

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

## **Chronology Of Events**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.



# Malarone - (62.5/25mg; Tablet)

| Generic Name          | Atovaquone and Proguanil Hydrochloride  | Innovator            | GlaxoSmithkline     |
|-----------------------|---|----------------------|---------------------|
| Dosage                | 62.5/25mg; Tablet   | Branded US Sales     | Less Than \$1000 mn |
| Probable FTF          | Less Than 5   | Known Para IV Filers | Less Than 5         |
| Other ANDA developers | Less Than 5   | Tentative Approvals  | None                |
| Final Approvals       | Less Than 5   | Generic Launches     | Less Than 5         |
| Indication            | Indicated for prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported |                      |                     |
| Complexities          | Yes   |                      |                     |

# **Chronology Of Events**

Please Contact contact@researchdelta.com to get Detailed Information.

### **Executive Summary**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

### **Patent Status**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

#### Launch Timelines and Competition

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

## **Chronology Of Events**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.